Trial · NCT01652976
Results by group29
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 29
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Progression Free Survival (PFS) | Dasatinib and mFOLFOX6 | 4 | 95% Confidence Interval 2.3 to 8.5 | months | |
| Response Rate | Dasatinib and mFOLFOX6 | 25 | 95% Confidence Interval 13.19 to 40.34 | percentage of subjects | |
| Freedom From Metastasis | Dasatinib and mFOLFOX6 | 65.5 | 95% Confidence Interval 45.7 to 82.1 | percentage of subjects | |
| Median Time To Progression | Dasatinib and mFOLFOX6 | 9.8 | 90% Confidence Interval 8.6 to 19.5 | months | |
| Median Overall Survival | Dasatinib and mFOLFOX6 | 10.6 | 95% Confidence Interval 6.9 to 12.7 | months | |
| Clinical Benefit Rate | Dasatinib and mFOLFOX6 | 56.82 | 95% Confidence Interval 41.03 to 71.65 | percentage of subjects | |
| Site of Failure | Dasatinib and mFOLFOX6 | Left pleural effusion | 1 | Participants | |
| Site of Failure | Dasatinib and mFOLFOX6 | Liver | 12 | Participants | |
| Site of Failure | Dasatinib and mFOLFOX6 | Lungs | 3 | Participants | |
| Site of Failure | Dasatinib and mFOLFOX6 | Pancreas/liver | 4 | Participants | |
| Site of Failure | Dasatinib and mFOLFOX6 | Peritoneal carcinomatosis | 1 | Participants | |
| Site of Failure | Dasatinib and mFOLFOX6 | peritoneal carcinomatosis/liver | 1 | Participants | |
| Site of Failure | Dasatinib and mFOLFOX6 | Spleen/liver | 1 | Participants | |
| Safety and Tolerability | Dasatinib and mFOLFOX6 | Percent of subjects experiencing a Grade 1 event | 88.6 | percentage of subjects | |
| Safety and Tolerability | Dasatinib and mFOLFOX6 | Percent of subjects experiencing a grade 2 event | 90.9 | percentage of subjects | |
| Safety and Tolerability | Dasatinib and mFOLFOX6 | Percent of subjects experiencing a Grade 3 event | 86.4 | percentage of subjects | |
| Safety and Tolerability | Dasatinib and mFOLFOX6 | Percent of subjects experiencing a Grade 4 event | 22.7 | percentage of subjects | |
| Safety and Tolerability | Dasatinib and mFOLFOX6 | Percent of subjects experiencing a grade 5 event | 9.1 | percentage of subjects | |
| Drug Compliance | Dasatinib and mFOLFOX6 | 93.2 | 95% Confidence Interval 81.3 to 98.6 | percentage of subjects | |
| Quality of Life, as Measured by the Cancer Therapy Satisfaction Questionnaire (CTSQ), 2007 | Dasatinib and mFOLFOX6 | Subscore difference for ET | -8.4 | 95% Confidence Interval -16.5 to -0.4 | score on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01652976/results